Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

An excellent overview. We discusssed the differences betwen current
used
flt3 inhibitors.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


An article published in BMT suggest that PT/Cy-haplo
recipients may
reconstitute CMV-specific T-cell immunity to the same extent
as patients
undergoing HLA-matched allo-HSCT
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Results of the international MRC UKALLXII/ECOG E2993 trial.
Out of the
1 752 patients who achieved CR, 11·7% underwent autologous
and 40·6%
allogeneic transplant, while in CR1. Of the autologous
patients, 43·2%
relapsed early and 3·4% relapsed late. However, among the
allogeneic
patients, 13·2% relapsed early and only 1·3%...


Excellent review. The most of the newly approved drugs are
for pts >75
years. The "problems" of the approval trials are
discussed. AS the
authro points:
Don’t trust the horse, Trojans. Whatever it is, I fearthe
Greeks even
bearing gifts.)—Virgi
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou,...


A combination of phenotypic and functional immune assays enables
risk-stratification of patients with viral infections after
transplantFunctional immune monitoring can help identify patients
in need of additional antiviral intervention
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


A retrospective study, The combination of
thiotepa, busulfan fludarabine (TBF) reduces the risk of relapse in
patients with remission AML, as compared to myeloablative busulfan
fludarabine (BUFLU)The effect is independt of donor type and GvHD
prophylaxis.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


A quiz presentation with real examples.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Prophylaxis and management of graft versus host disease after
stem-cell transplantation for haematological malignancies: updated
consensus recommendations of the European Society for Blood and
Marrow Transplantation.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


